Research reveals that over 15 million people in the US, UK, Germany, and France are unaware they have metabolic dysfunction-associated steatotic liver disease, a condition linked to severe health risks. Experts call for increased screenings and diagnosis rates.
In a groundbreaking achievement, scientists have developed the first gene-editing medicine tailored for a baby suffering from a rare DNA condition. After successful treatments, KJ Muldoon is now healthier and ready to go home, showcasing a promising future for gene therapies.
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
New research reveals that exercise can enhance brain function even when ketone production is low, offering hope for those at risk of cognitive decline, particularly with liver issues.
